ERBB2 and breast carcinoma: Nevertheless tumour-based lymphocytic ratio was prognostic in HER2 breast cancer, and the addition of ImmunoSkew to the low lymphocytic infiltrate group further stratified patients with statistical significance (blue vs red groups: p = 0.0039, Fig. 5B).